News

Targeted Oncology15m
Adagrasib Plus Pembrolizumab Shows Best Efficacy in PD-L1–High NSCLC
During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with ...
Targeted Oncology1d
KRAS Inhibitors Show Efficacy in Randomized NSCLC Trials
During a live event, Christine Bestvina, MD, reviewed outcomes from the phase 3 KRYSTAL-12 and CodeBreak 200 trials in the ...